PYX Resources: Achieving volume and diversification milestones. Watch the video here.
No support from British funds to keep the momentum.... shameful. Hopefully a Stateside or French acquirer will show them just how cutting-edge and must-have this tech is.
All three factors needed to drive this back to 'infinity and beyond' are in play ..... plus we now have fomo!
120p looking achievable today given momentum....
Buying pressure, volume and multie attempts to break the 114.2.......this time we succeed.
Big increase in volumes over last 5 trading sessions on NYSE and building nicely early-on here. Expecting a nice little gap-jump soon.
Chart is looking good for a concerted attack on 120p as the next hurdle.....
Oxford Nanotech are centre stage at London conference next Wednesday 22nd May so should provide good platform from here.
It's the groundbreaking innovators that will mold the future. The NHS will be driven by the likes of ONT.
https://www.england.nhs.uk/healthcare-science/personalisedmedicine/
Oxford Nano is like early AI in that it is on the cusp of transforming the future. Personalised medicine is here and will explode in the next decade. Oxford Nano is breaking all the moulds as its tech opens the doors. It has the cash and runway. Hold tight as the likes of bioMerieux and other big pharmas eye up how they can get hold of this IP. Interesting times ahead imo.
Anti-takeover protection ends this year and the share price is a quarter of that at IPO in 2021.
Slaughter and May
Devised anti-takeover IPO strategy for Oxford Nano - float price £4.25 per share.
We helped design and implement ONT’s innovative takeover-defence We helped design and implement ONT’s innovative takeover-defence share structure, granting the CEO (or certain replacements, in the event of the CEO no longer being available) voting control of ONT in the event of an undesired takeover or other change of control for three years post-IPO.ements, in the event of the CEO no longer being available) voting control of ONT in the event of an undesired takeover or other change of control for three years post-IPO.
..........the IPO was in 2021......it is now 2024.
Can't believe this is still hovering around this low level when June 6th signals a time that stakebuilding and takeover stakes rise post IPO. Grossly undervalued as recent director buys appear to agree.
Looking interesting. US investors seeing value - or stake building??
Big jump in traded volume on NYSE today...over 535% above 65 day average. Interesting.....it's been around 25% over past 2 weeks.
And another whopping uncrossing trade today. That's £0.75m yesterday and £0.88m today. Things are shaping up as the few shorters bail out.
BioMerieux SA and Illumina could both be interested enough to secure control here. That would certainly perk up wider interest. Undervalued significantly imo given huge potential and fact that bioMerieux SA payed twice this price per share for its c 7%.
This little holding could have interesting significance also from June 6th. Very undervalued and ideal tech for big pharma.
Nice tidy £0.75m uncrossing trade there.